News Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug Buoyed by data from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's drug from its Brainshuttle programme.
News UK sets aside £2m for digitally-enhanced dementia tests The UK is providing £2m in funding to allow digital assessment to be added to a highly-anticipated trial of blood tests for diagnosing dementia.
News End of the line for Cassava's troubled Alzheimer's programme The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end.
News Augustine decloaks with $85m for nerve disease programme Belgian start-up Augustine raises €78m ($85m) in first-round funding for HDAC6 inhibitors headed by a candidate for Charcot-Marie-Tooth disease.
News Bayer gains ground in two-fronted Parkinson's offensive Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.
News Algorithm spots common sleep disorder linked to dementia An AI algorithm can help detect REM sleep behaviour disorder, which affects millions of people and is a warning signal for neurological diseases.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.